2. Search Result
Search Result
Results for "

Fluid secretion

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

6

Peptides

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B2132
    Tryptamine
    1 Publications Verification

    3-(2-Aminoethyl)indole~2-(3-Indolyl)ethylamine

    		 Endogenous Metabolite 5-HT Receptor Aryl Hydrocarbon Receptor Neurological Disease Metabolic Disease
    Tryptamine is a selective, blood-brain-penetrating 5-HT4 receptor agonist (EC50=1-3 mM) and an endogenous ligand of the aryl hydrocarbon receptor (AHR) (Kd=10-50 nM). Tryptamine promotes intestinal anion secretion and fluid transport by activating G protein-coupled receptors (GPCRs) and accelerates gastrointestinal motility. Tryptamine regulates Th17/Treg balance to inhibit neuroinflammation, competitively binds to 5-HT receptors to regulate central nervous system activity, and participates in temperature regulation and spinal reflex regulation as a neuromodulator. Tryptamine can be used to study intestinal motility disorders such as functional constipation, and has shown significant efficacy in multiple sclerosis models .
    Tryptamine
  • HY-B0588
    Brinzolamide
    5+ Cited Publications

    AL-4862

    		 Carbonic Anhydrase Cardiovascular Disease Others Neurological Disease
    Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
    Brinzolamide
  • HY-B0679
    Lubiprostone
    1 Publications Verification

    RU-0211; SPI-0211

    		 Chloride Channel CFTR Glutathione Peroxidase NO Synthase TNF Receptor Metabolic Disease
    Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research .
    Lubiprostone
  • HY-B0606
    Diquafosol tetrasodium
    5 Publications Verification

    INS365

    		 P2Y Receptor Inflammation/Immunology
    Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
    Diquafosol tetrasodium
  • HY-W096638A
    Glycerophosphocholine

    (S)-Glycerolphosphocholine

    		 Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Glycerophosphocholine ((S)-Glycerolphosphocholine) is an orally active metabolite that crosses the blood-brain barrier. Glycerophosphocholine acts as a precursor of acetylcholine, a specific marker for phosphatidylcholine breakdown, a major water-soluble storage form of choline, and an intermediate in phosphatidylcholine metabolism. Glycerophosphocholine is specifically elevated in the cerebrospinal fluid of Alzheimer's disease models, and it also promotes growth hormone secretion and fat oxidation. Glycerophosphocholine is also a potential biomarker for breast cancer .
    Glycerophosphocholine
  • HY-156131
    Loperamide
    Maximum Cited Publications
    12 Publications Verification

    ADL 2-1294

    		 Opioid Receptor Neurological Disease Inflammation/Immunology
    Loperamide (ADL 2-1294) is selective and orally active μ opioid receptor agonist with Ki valuess of 3, 48 and 1156 nM against μ, δ and κ opioid receptor, respectively. Loperamide produces antinociception and antihyperalgesia. Loperamide exhibits peripheral selectivity, enhancing fluid, electrolyte, and glucose absorption, reversing PGE2 (HY-101952)- and Cholera toxin (HY-P1446)-induced intestinal secretion, and reducing intestinal motility. Loperamide can be used for the researches of inflammatory pain and protracted diarrhoea .
    Loperamide
  • HY-105017
    Evodenoson

    ATL 313; DE 112

    		 Adenosine Receptor Infection Inflammation/Immunology
    Evodenoson is a selective agonist of the A2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) .
    Evodenoson
  • HY-P1784A
    Secretin, canine TFA

    		Secretin Receptor Endocrinology
    ecretin, canine TFA is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine TFA can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .
    Secretin, canine TFA
  • HY-B1202
    Alrestatin
    1 Publications Verification

    AY-22284

    		 Aldose Reductase Metabolic Disease
    Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases .
    Alrestatin
  • HY-B0680
    Lubiprostone (hemiketal)

    RU-0211 (hemiketal); SPI-0211 (hemiketal)

    		 Chloride Channel Others Cancer
    Lubiprostone (hemiketal) (RU-0211 (hemiketal)) is a selective chloride channel 2 (CLCN2) activator. Lubiprostone (hemiketal) is used to treat chronic idiopathic constipation and opioid-induced constipation by activating CLCN2 channels to increase chloride ion secretion in the intestine, thereby increasing intestinal fluid secretion and enhancing intestinal peristalsis. Lubiprostone (hemiketal) can be used in the study of chronic constipation and cancer .
    Lubiprostone (hemiketal)
  • HY-P11380
    Capa-2

    		Neurotensin Receptor Calcium Channel NO Synthase Guanylate Cyclase Neurological Disease Metabolic Disease
    Capa-2 is a neuropeptide. Capa-2 activates calcium ion influx, stimulates the production of NO, activates soluble guanylate cyclase (sGC), increases intracellular cGMP, and drives ion and fluid secretion. Capa-2 can be used in studies of diuresis .
    Capa-2
  • HY-B0588A
    Brinzolamide hydrochloride

    AL-4862 hydrochloride

    		 Carbonic Anhydrase Neurological Disease
    Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
    Brinzolamide hydrochloride
  • HY-P2537
    Apelin-12
    2 Publications Verification

    		 HIV Apelin Receptor (APJ) Others
    Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect .
    Apelin-12
  • HY-B2078
    Eprazinone

    		Neurokinin Receptor Inflammation/Immunology
    Eprazinone can enhance lung function and arterial oxygen levels and can be used in the study of chronic bronchitis. Higher doses of eprazinone increased phospholipid levels and decreased neutral lipid content in bronchoalveolar lavage (BAL) fluid, but had no effect on protein and cell levels in BAL. Eprazinone dose-dependently reduced short-circuit current (Isc), primarily by reducing chloride secretion at lower concentrations and affecting sodium and chloride transport at higher doses. Eprazinone may exert its anti-inflammatory effects by regulating BAL lipid composition and airway ion transport .
    Eprazinone
  • HY-P1581
    Ceratotoxin A

    		Bacterial Infection
    Ceratotoxin A, a 29-residue peptide isolated from the accessory gland secretion fluid, with strong anti-bacterial activity.
    Ceratotoxin A
  • HY-113929
    Loperamide oxide

    R-58425

    		 Opioid Receptor Inflammation/Immunology
    Loperamide oxide (R-58425) is a orally active prodrug of the Loperamide (HY-156131). Loperamide oxide incubation with the contents of the intestinal lumen inhibits fluid secretion under aerobic conditions .
    Loperamide oxide
  • HY-P1784
    Secretin, canine

    		Secretin Receptor Endocrinology
    Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway .
    Secretin, canine
  • HY-113929R
    Loperamide oxide (Standard)

    R-58425 (Standard)

    		 Opioid Receptor Reference Standards Inflammation/Immunology
    Loperamide oxide (Standard) is the analytical standard of Loperamide oxide. This product is intended for research and analytical applications. Loperamide oxide (R-58425) is a orally active prodrug of the Loperamide (HY-156131). Loperamide oxide incubation with the contents of the intestinal lumen inhibits fluid secretion under aerobic conditions .
    Loperamide oxide (Standard)
  • HY-B0588AS
    Brinzolamide-d5 hydrochloride

    AL-4862-d5 hydrochloride

    		 Carbonic Anhydrase Neurological Disease
    Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
    Brinzolamide-d5 hydrochloride
  • HY-B0588R
    Brinzolamide (Standard)

    AL-4862 (Standard)

    		 Reference Standards Carbonic Anhydrase Others Neurological Disease
    Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
    Brinzolamide (Standard)
  • HY-B1202A
    Alrestatin sodium

    AY-22284A

    		 Aldose Reductase Metabolic Disease
    Alrestatin (AY-22284) sodium is an aldose reductase inhibitor. Alrestatin sodium reduces fructose levels in the uterine fluid of mice. Alrestatin sodium interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin sodium decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin sodium enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin sodium can be used in studies related to diabetes and reproductive diseases .
    Alrestatin sodium
  • HY-B0679R
    Lubiprostone (Standard)

    RU-0211 (Standard); SPI-0211 (Standard)

    		 Reference Standards Chloride Channel CFTR Glutathione Peroxidase NO Synthase TNF Receptor Metabolic Disease
    Lubiprostone (Standard) is the analytical standard of Lubiprostone. This product is intended for research and analytical applications. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research .
    Lubiprostone (Standard)
  • HY-B0679S
    Lubiprostone-d7

    RU-0211-d7; SPI-0211-d7

    		 Isotope-Labeled Compounds Chloride Channel CFTR Glutathione Peroxidase NO Synthase TNF Receptor Metabolic Disease
    Lubiprostone-d7 (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research .
    Lubiprostone-d7
  • HY-B1202R
    Alrestatin (Standard)

    AY-22284 (Standard)

    		 Reference Standards Aldose Reductase Metabolic Disease
    Alrestatin (AY-22284) Standard is the analytical standard of Alrestatin (HY-B1202). This product is intended for research and analytical applications. Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases.
    Alrestatin (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: